Company news
Scisparc Ltd. (NASDAQ:SPRC) news
Scisparc Ltd. news releases on 6ix. Latest, Jun 29, 2022: SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110…
Press releases — page 4
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
June 28, 2022
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
June 22, 2022
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins
June 14, 2022
SciSparc's Board of Directors Provides Strategic Decision
June 8, 2022
SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market
May 31, 2022
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
May 26, 2022
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
May 25, 2022
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
May 9, 2022
SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update
May 1, 2022
SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
March 30, 2022
Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain
March 29, 2022
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial
March 16, 2022
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
March 9, 2022
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
March 7, 2022
SciSparc Presents New Leadership Lineup
January 26, 2022
SciSparc Advances Its Phase IIb Clinical Trial in Patients with Tourette Syndrome with its Proprietary Drug Candidate SCI-110
January 17, 2022
SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease
January 5, 2022
SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders
January 3, 2022
SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today
December 21, 2021